
    
      The sponsor decided to terminate the program after evaluation of safety and efficacy data at
      the dose levels tested (Part A). The decision to discontinue the birabresib program was based
      on limited efficacy signals and was not due to safety-related concerns. No participants
      entered or were treated in Part B of the study.
    
  